인터페론-감마 엔도타입에 의한 패혈증에서 예상되는 임상적 이점을 위한 Emapalumab 치료(EMBRACE 시험) (EMBRACE)
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The EMBRACE trial aims to generate proof-of-concept if treatment with emapalumab, a monoclonal antibody which blocks IFNγ signaling, may improve the outcome of patients with sepsis driven by the IDS endotype. In EMBRACE, two different dose regimens of emapalumab are administered in order to: a) investigate which dose regimen may provide most of efficacy in the decrease of SOFA score, a new endpoint for sepsis suggested already by others; b) investigate which dose regimen better attains the pharmacodynamic goal of emapalumab defined as the decrease of blood CXCL9; and c) compare the efficacy of the two dose regimens with placebo treated patients.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Alexandroupoli, 그리스
- Intensive Care Unit, Alexandroupolis University General Hospital
-
Athens, 그리스
- 4th Department of Internal Medicine, ATTIKON University General Hospital
-
Athens, 그리스
- Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
-
Athens, 그리스
- 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, 그리스
- Intensive Care Unit I, KAT Attica General Hospital
-
Athens, 그리스
- Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, 그리스
- Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
-
Athens, 그리스
- Intensive Care Unit, Asklipieio Voulas General Hospital
-
Athens, 그리스
- Intensive Care Unit, Ippokrateio Athens General Hospital
-
Athens, 그리스
- Intensive Care Unit, Laiko Athens General Hospital
-
Athens, 그리스
- New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
-
Athens, 그리스
- Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
-
Pátrai, 그리스
- Intensive Care Unit, Patras University General Hospital
-
Thessaloniki, 그리스
- 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
-
Thessaloniki, 그리스
- Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
-
Thessaloniki, 그리스
- Intensive Care Unit, 424 General Military Training Hospital
-
Thessaloniki, 그리스
- Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
-
Thessaloniki, 그리스
- Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
-
Thessaloniki, 그리스
- Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
-
Thessaloniki, 그리스
- Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
-
Thessaloniki, 그리스
- Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
-
-
Attica
-
Elefsina, Attica, 그리스
- 1st Department of Internal Medicine, Thriasio Elefsis General Hospital
-
Kifissia, Attica, 그리스
- Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
-
-
Crete
-
Heraklion, Crete, 그리스
- Intensive Care Unit, University General Hospital of Heraklion
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Provide written informed consent
- Adults (≥18 years) of male or female sex
- Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections.
- Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more.
- Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age.
- Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay.
- Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9.
Exclusion Criteria:
- Body weight more than 104 kg
- Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
- Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
- Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
- Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
- Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
- Vaccination the last 12 weeks before screening with BCG vaccine
- Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
- Known allergy or hypersensitivity reactions to emapalumab
- Patients living with the human immunodeficiency virus (HIV)
- Patients with stage IV solid or hematologic malignancy
- Patients with neutropenia (less than 1,000 neutrophils/mm3)
- Patients transplanted for solid organ or stem cells
- Pregnancy or lactation
- Participation in any other interventional trial the last 28 days prior to day 1
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Standard-of-care (SoC) treatment and placebo drug. |
250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply |
|
활성 비교기: Emapalumab Group 1
SoC treatment and a low dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
다른 이름들:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
다른 이름들:
|
|
활성 비교기: Emapalumab Group 2
SoC treatment and a high dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
다른 이름들:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Decrease of SOFA score by the end-of-treatment
기간: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
The study primary endpoint is the decrease of SOFA score by the end-of-treatment (EOT). This is defined as either a) at least 1.4 points decrease of mean SOFA score calculated between days 1 and EOT from SOFA score of day 0; OR b) at least 2 points decrease of SOFA at EOT from day 0. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EOT에 의한 SOFA 점수 응답을 달성하기 위해 각 그룹에 필요한 복용량 수.
기간: 각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
|
|
28일 사망률
기간: 등록일부터 등록 후 28일까지입니다.
|
등록일부터 등록 후 28일까지입니다.
|
|
|
The rate of serious TEAEs and non-serious TEAEs
기간: From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
Comparison of the rate of serious TEAEs and non-serious TEAEs between the three groups of treatment. |
From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
|
The change of the SOFA score from day 0 until day 7
기간: From enrollment (day 0) to 8 days after enrollment (day 7).
|
Comparison of the change of the SOFA score from day 0 until day 7 |
From enrollment (day 0) to 8 days after enrollment (day 7).
|
|
The change of the SOFA score from 0 until day 28
기간: From enrollment to 28 days after enrollment.
|
Comparison of the change of the SOFA score from 0 until day 28 |
From enrollment to 28 days after enrollment.
|
|
The change of the SOFA score from 0 until EOT
기간: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the change of the SOFA score from 0 until EOT |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The pharmacokinetics of emapalumab
기간: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the pharmacokinetics of emapalumab |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.
기간: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment
기간: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
기타 결과 측정
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
치료에 대한 단백질체 프로필에 대한 세 가지 치료 그룹 간의 비교
기간: 각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
|
치료에 대한 전사체 프로필의 변화에 대한 세 가지 치료 그룹 간의 비교
기간: 각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
|
CD45/CD14 단핵구의 HLA-DR 수용체 절대 수와 비교한 SII용 현장 진료 SepsisLoop의 진단 성능.
기간: 각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
|
연구 집단을 IDS로 분류하는 진단 도구의 잠재적인 개발을 위한 스크리닝 시 임상 데이터 및 병상 바이오마커 수준
기간: 각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
|
패혈증 인구를 다양한 하위 그룹으로 분류하는 스크리닝 시 예후 바이오마커 수준
기간: 각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
각 연구 참가자의 등록부터 연구 약물 치료 종료까지 2일부터 29일까지입니다.
|
공동 작업자 및 조사자
수사관
수사관
- 연구 의자: Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Studies of Sepsis
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- EMBRACE
- 2024-515255-38-00 (씨티스)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .